Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Abbott Reports Double-Digit Ongoing Earnings-Per-Share Growth in Fourth Quarter and Full-Year 2011


News provided by

Abbott

25 Jan, 2012, 12:46 GMT

Share this article

Share toX

Share this article

Share toX

ABBOTT PARK, Illinois, January 25, 2012 /PRNewswire/ --


-- Fourth Quarter Ongoing EPS of $1.45, Up 11.5 Percent --


-- On Track to Separate into Two Leading Health Care Companies --

Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2011.

  • Diluted earnings per share, excluding specified items, were $1.45, at the high end of Abbott's previous guidance range, reflecting 11.5 percent growth. Diluted earnings per share under Generally Accepted Accounting Principles (GAAP) were $1.02, including specified items.
  • Worldwide sales increased 4.1 percent to $10.4 billion, including a favorable 0.2 percent effect of foreign exchange. Emerging markets sales were $2.5 billion, representing nearly 25 percent of total sales, with particularly strong growth in Nutritionals, Vascular and Diagnostics.
  • Fourth quarter results included an adjusted gross margin ratio of nearly 64 percent, driven by improved efficiencies across a number of operating divisions, product mix, and the effect of foreign exchange.
  • In 2011, Abbott continued to advance its broad-based pipeline, and launched several new products or indications across our Pharmaceuticals, Medical Products, Nutritionals and Diagnostics businesses.
  • Abbott generated record operating cash flow of more than $9 billion in 2011. The company will resume share repurchase activity in 2012.

"Despite another challenging year for the global economy, Abbott again delivered leading performance, including strong sales and ongoing earnings-per-share growth," said Miles D. White, chairman and chief executive officer, Abbott. "2011 was a significant year for Abbott, with the announced plan to separate into two leading health care companies in research-based pharmaceuticals and diversified medical products, each offering shareholders distinct identities with unique investment opportunities. We remain on track to complete the separation by the end of 2012."

The following is a summary of fourth-quarter 2011 sales by major business category.

 
                                        Sales ($ in millions)
                                     U.S.     Int'l    Total
 
    Total Sales                      4,471    5,906    10,377
 
    Proprietary Pharmaceuticals      2,806    1,974     4,780
 
    Nutritionals                       679      877     1,556
 
    Established Pharmaceuticals(a)      --    1,389     1,389
 
    Core Laboratory Diagnostics        174      701       875
 
    Molecular Diagnostics               60       66       126
 
    Point of Care Diagnostics           60       19        79
 
    Vascular                           374      452       826
 
    Diabetes Care                      136      215       351
 
    Medical Optics                      99      187       286
 
    Other Sales(b)                      83       26       109
 
 
                                                  % Change vs. 4Q10
                                              Int'l                          Total
                          U.S.    Operational       Reported       Operational   Reported
 
    Total Sales            4.3       3.7             4.0              3.9           4.1
 
    Proprietary
    Pharmaceuticals        5.7       7.4             8.3              6.3           6.7
 
    Nutritionals           5.8      10.5            10.8              8.4           8.6
 
    Established
    Pharmaceuticals(a)     n/a      (3.3)           (4.6)            (3.3)         (4.6)
 
    Core Laboratory
    Diagnostics           10.1       4.2             4.7              5.3           5.7
 
    Molecular
    Diagnostics            9.8      12.2            11.2             11.1          10.6
 
    Point of Care
    Diagnostics            8.3       5.1             6.5              7.5           7.8
 
    Vascular              (6.3)      4.5             7.0             (0.7)          0.6
 
    Diabetes Care          7.1       1.5             2.2              3.5           4.0
 
    Medical Optics        (3.9)      3.3             5.7              0.7           2.2
 
    Other Sales(b)       (10.8)      n/m             n/m              n/m           n/m
 

The following is a summary of twelve-month 2011 sales by major business category.

 
                                       Sales ($ in millions)
                                      U.S.     Int'l     Total
 
    Total Sales                      16,014    22,837    38,851
 
    Proprietary Pharmaceuticals       9,455     7,567    17,022
 
    Nutritionals                      2,653     3,353     6,006
 
    Established Pharmaceuticals(a)       --     5,413     5,413
 
    Core Laboratory Diagnostics         638     2,745     3,383
 
    Molecular Diagnostics               206       236       442
 
    Point of Care Diagnostics           232        69       301
 
    Vascular                          1,547     1,786     3,333
 
    Diabetes Care                       544       820     1,364
 
    Medical Optics                      396       715     1,111
 
    Other Sales(b)                      343       133       476
 
                                             % Change vs. 12M10
                                            Int'l                      Total
                         U.S.     Operational   Reported     Operational    Reported
 
    Total Sales            5.4      9.4          14.3            7.7            10.5
 
    Proprietary
    Pharmaceuticals        8.1      9.4          14.9            8.7            11.0
 
    Nutritionals           2.5     10.1          13.9            6.6             8.6
 
    Established
    Pharmaceuticals(a)    n/a      15.5          19.8           15.5            19.8
 
    Core Laboratory
    Diagnostics            6.0      3.7           8.4            4.1             7.9
 
    Molecular
    Diagnostics            8.5     16.1          20.7           12.4            14.7
 
    Point of Care
    Diagnostics            9.7      8.9          12.8            9.5            10.4
 
    Vascular             (6.9)     10.0          16.6            1.2             4.4
 
    Diabetes Care          6.3      2.1           7.4            3.8             7.0
 
    Medical Optics       (2.5)      2.6           8.9            0.7             4.6
 
    Other Sales(b)        23.6    (27.6)        (27.0)           3.4             3.6
       Notes:       1) See "Consolidated Statement of Earnings" for more
                       information.
                    2) "Operational" growth reflects percentage change over
                       the prior year excluding the impact of exchange rates.
 
    (a) Established Pharmaceuticals includes sales of branded generics
    outside of the United States.
    (b) Includes sales primarily from Contract Pharmaceutical Manufacturing
    and Animal Health.
 
    n/a = Not applicable
    n/m = Percent change is not meaningful.
 

The following is a summary of fourth-quarter 2011 sales for select products.

 
                                    Sales ($ in millions)
                                   U.S.      Int'l    Total
 
    HUMIRA                          1,077    1,101    2,178
 
    Pediatric Nutritionals            338      505      843
 
    Adult Nutritionals                338      372      710
 
    Coronary Stents                   234      274      508
 
    TRILIPIX/TriCor (fenofibrate)     409       74      483
 
    Kaletra                           100      188      288
 
    Niaspan                           258       --      258
 
    Lupron                            139       69      208
 
    Synthroid                         134       29      163
 
                                             % Change vs. 4Q10
                                          Int'l                    Total
                       U.S.      Operational Reported     Operational Reported
 
    HUMIRA              22.9             8.8      9.8          15.4     15.9
 
    Pediatric
    Nutritionals        11.2            14.9     15.3          13.4     13.6
 
    Adult
    Nutritionals         1.1             5.0      5.3           3.0      3.2
 
    Coronary Stents     (5.7)            0.1      3.0          (2.7)    (1.2)
 
    TRILIPIX/TriCor
    (fenofibrate)       (2.2)          (14.3)   (14.8)         (4.2)    (4.3)
 
    Kaletra             (9.8)          (17.9)   (18.3)        (15.3)   (15.6)
 
    Niaspan            (10.0)            n/a      n/a         (10.0)   (10.0)
 
    Lupron               6.9            (0.8)    (1.5)          4.2      4.0
 
    Synthroid            2.4             2.5      0.2           2.4      2.0

The following is a summary of twelve-month 2011 sales for select products.

 
                                    Sales ($ in millions)
                                     U.S.    Int'l    Total
 
    HUMIRA                          3,427    4,505    7,932
 
    Pediatric Nutritionals          1,268    1,926    3,194
 
    Adult Nutritionals              1,368    1,427    2,795
 
    Coronary Stents                   955    1,123    2,078
 
    TRILIPIX/TriCor (fenofibrate)   1,372      320    1,692
 
    Kaletra                           326      844    1,170
 
    Niaspan                           976       --      976
 
    Lupron                            540      270      810
 
    Synthroid                         522      116      638
 
                                            % Change vs. 12M10
                                         Int'l                    Total
                       U.S.      Operational Reported     Operational Reported
 
    HUMIRA              19.3         16.0      22.6            17.4     21.1
 
    Pediatric
    Nutritionals         5.0         11.7      14.9             8.8     10.7
 
    Adult
    Nutritionals         1.7          8.0      12.6             4.8      7.0
 
    Coronary Stents     (8.8)        10.0      17.0             0.1      3.5
 
    TRILIPIX/TriCor
    (fenofibrate)        1.2         23.6      28.8             4.7      5.5
 
    Kaletra            (10.3)        (8.9)     (5.4)           (9.3)    (6.8)
 
    Niaspan              5.3          n/a       n/a             5.3      5.3
 
    Lupron              11.8         (3.0)      1.8             6.5      8.2
 
    Synthroid           15.6          7.1      11.5            14.0     14.8
    Notes: 1) See "Consolidated Statement of Earnings" for more information.
           2) "Operational" growth reflects percentage change over the prior
              year excluding the impact of exchange rates.
 
    n/a = Not applicable

Business Highlights

Announced Plans to Separate Abbott into Two Leading Health Care Companies
Announced plans to separate into two publicly-traded companies, one in diversified medical products and the other in research-based pharmaceuticals. The diversified medical products company will consist of Abbott's branded generic pharmaceutical, devices, diagnostic and nutritional businesses, and will retain the Abbott name. The research-based pharmaceutical company will include Abbott's current portfolio of proprietary pharmaceuticals and biologics and will be named later.

Received U.S. Approval for XIENCE PRIME Drug Eluting Stent
Received U.S. Food and Drug Administration (FDA) approval for XIENCE PRIME™ for the treatment of coronary artery disease. Abbott now offers an expanded range of drug eluting stents, including long lengths up to 38 mm. XIENCE PRIME features an enhanced stent design and delivery system.

Announced Expanded Collaboration with Reata Pharmaceuticals
Announced plans to jointly develop and commercialize Reata's portfolio of second-generation oral antioxidant inflammation modulators (AIMs). The collaboration includes molecules in a broad range of therapeutic areas, including pulmonary, central nervous system disorders and immunology.

Presented Promising New Data on HCV Compounds
Presented interim results from two Phase 2 studies in Hepatitis C (HCV) patients treated with Abbott's ritonavir-boosted protease inhibitor ABT-450, a polymerase inhibitor and ribavirin for 12 weeks. Early results show very high cure rates were achieved in genotype 1a and 1b patients with only 12 weeks of interferon-free therapy. In addition, we initiated a Phase 2b interferon-free combination study.

Presented New Daclizumab Data at Multiple Sclerosis Congress
Announced with our partner company Biogen Idec additional results from the SELECT Phase 2b trial, the first of two registrational studies designed to evaluate daclizumab high-yield process (DAC HYP) in people with relapsing-remitting multiple sclerosis. Results showed that DAC HYP met the trial's primary endpoint by significantly reducing the annualized relapse rate by 54 percent in the 150 mg dose group and 50 percent in the 300 mg dose group compared to the placebo group at one year.

Secured FDA Clearance for Acute Myeloid Leukemia Test
Received 510(k) clearance from the U.S. FDA for a new in vitro diagnostic test to aid in determining the prognosis of patients with acute myeloid leukemia (AML). Abbott's Vysis EGR1 FISH Probe Kit is the third Abbott FISH assay approved or cleared this year by the FDA for oncology applications.

Launched New Line of Glucerna Nutrition Products for People with Diabetes
Introduced new Glucerna® Hunger Smart™ nutrition shakes and bars for the more than 25 million Americans with diabetes.

Expanded Use of ARCHITECT Platform with Additional Assay Approvals
Received approval in the European Union to market a new diagnostic test for detection of hepatitis B surface antigen (HBsAg), performed on Abbott's ARCHITECT® laboratory testing platform. Additionally, Abbott received clearance from the U.S. FDA for a fully-automated 25-OH Vitamin D assay.

Initiated Clinical Trials to Evaluate Drug Eluting BVS
Announced the initiation of the ABSORB II trial to evaluate the safety, efficacy and performance of the Absorb™ bioresorbable vascular scaffold (BVS) compared to XIENCE PRIME. Absorb has CE Mark and is authorized for sale in Europe for the treatment of coronary artery disease. Additionally, we initiated a first-of-its-kind clinical trial in Europe evaluating our novel Esprit™ drug-eluting BVS in patients with peripheral artery disease.

Abbott issues ongoing earnings-per-share outlook for 2012

Abbott is issuing ongoing earnings-per-share guidance for the full-year 2012 of $4.95 to $5.05, reflecting another year of strong performance.

Abbott forecasts specified items for the full-year 2012 of approximately $0.35 per share, primarily associated with acquisition integration and cost reduction initiatives. This forecast of specified items excludes one-time costs related to the planned separation of Abbott into two companies, which will be quantified at a later date. Including these specified items, projected earnings per share under Generally Accepted Accounting Principles (GAAP) would be $4.60 to $4.70 for the full-year 2012.

Abbott declares 352nd quarterly dividend

On Dec. 9, 2011, the board of directors of Abbott declared the company's quarterly common dividend of 48 cents per share. The cash dividend is payable Feb. 15, 2012, to shareholders of record at the close of business on Jan. 13, 2012. This marks the 352nd consecutive dividend paid by Abbott since 1924.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 91,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com. Abbott will webcast its live fourth-quarter earnings conference call through its Investor Relations Web site at http://www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the call will be available after 11 a.m. Central time.

- Private Securities Litigation Reform Act of 1995 -

A Caution Concerning Forward-Looking Statements

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995, including the planned separation of the research-based pharmaceutical company from the diversified medical products company and the expected financial results of the two companies after the separation. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2010, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments.

 
                      Abbott Laboratories and Subsidiaries
                      Consolidated Statement of Earnings
                  Fourth Quarter Ended December 31, 2011 and 2010
                      (in millions, except per share data)
                                  (unaudited)
 
                                             2011       2010      % Change
 
    Net Sales                              $ 10,377    $ 9,968         4.1
 
    Cost of products sold                     3,838      4,045        (5.1)  1)
    Research and development                  1,152      1,058         8.9
    Acquired in-process research and
    development                                 400        238         n/m
    Selling, general and administrative       2,905      2,797         3.9
    Total Operating Cost and Expenses         8,295      8,138         1.9
 
    Operating earnings                        2,082      1,830        13.8
 
    Net interest expense                        102       129        (20.8)
    Net foreign exchange (gain) loss            (2)       (19)         n/m
    Other (income) expense, net                  28       (48)         n/m
    Earnings before taxes                     1,954      1,768        10.5
    Taxes on earnings                           335        327         2.5
    Net Earnings                            $ 1,619    $ 1,441        12.3
 
    Net Earnings Excluding Specified
    Items, as described below               $ 2,295    $ 2,025        13.3  2)
 
    Diluted Earnings per Common Share        $ 1.02     $ 0.92        10.9
 
    Diluted Earnings Per Common Share,
    Excluding Specified Items,
    as described below                       $ 1.45     $ 1.30        11.5  2)
 
    Average Number of Common Shares
    Outstanding Plus Dilutive
    Common Stock Options and Awards           1,577      1,556
    1)          Cost of products sold declined across all of Abbott's major
                businesses as a result of continued efficiency initiatives.
 
    2)          2011 Net Earnings Excluding Specified Items excludes
                after-tax charges of $400 million, or $0.25 per share,
                relating to acquired in-process research and development
                related to the Reata collaboration, $124 million, or $0.08
                per share, associated with the acquisition of Solvay
                Pharmaceuticals, and $152 million, or $0.10 per share, for
                other restructuring and integration charges.
 
                2010 Net Earnings Excluding Specified Items excludes
                after-tax charges of $346 million, or $0.23 per share,
                related primarily to the acquisitions of Solvay
                Pharmaceuticals and Piramal Healthcare Solutions, as well as
                other cost reduction initiatives, and $238 million, or $0.15
                per share, relating to acquired in-process research and
                development related to the Reata collaboration.
 
    NOTE: See attached questions and answers section for further explanation
    of Consolidated Statement of Earnings line items.
 
    n/m = Percent change is not meaningful.
 
                      Abbott Laboratories and Subsidiaries
                       Consolidated Statement of Earnings
                  Twelve Months Ended December 31, 2011 and 2010
                      (in millions, except per share data)
                                  (unaudited)
 
                                            2011        2010      % Change
 
    Net Sales                             $ 38,851    $ 35,167        10.5
 
    Cost of products sold                   15,541      14,665         6.0
    Research and development                 4,129       3,725        10.9
    Acquired in-process research and
    development                                673         313         n/m
    Selling, general and administrative     12,756      10,376        22.9   1)
    Total Operating Cost and Expenses       33,099      29,079        13.8
 
    Operating earnings                       5,752       6,088        (5.5)
 
    Net interest expense                       445         448        (0.6)
    Net foreign exchange (gain) loss          (50)        (11)         n/m
    Other (income) expense, net                158        (62)         n/m   2)
    Earnings before taxes                    5,199       5,713        (9.0)
    Taxes on earnings                          470       1,087         n/m   3)
    Net Earnings                           $ 4,729     $ 4,626         2.2
 
    Net Earnings Excluding Specified
    Items, as described below              $ 7,331     $ 6,501        12.8   4)
 
    Diluted Earnings per Common Share       $ 3.01      $ 2.96         1.7
 
    Diluted Earnings Per Common Share,
    Excluding Specified Items,
    as described below                      $ 4.66      $ 4.17        11.8   4)
 
    Average Number of Common Shares
    Outstanding Plus Dilutive
    Common Stock Options and Awards          1,567       1,556
      1)        2011 Selling, general and administrative expense includes
                $1.5 billion of litigation reserves related to ongoing
                settlement discussions in the previously disclosed
                investigation by the U.S. Department of Justice, through the
                U.S. Attorney for the Western District of Virginia, related
                to Depakote. The discussions are ongoing, and until
                concluded, there can be no certainty about definitive
                resolution.
 
      2)        Other (income) expense, net for 2011 includes a charge of
                $137 million for the impact of Abbott's change to a calendar
                year end for the international operations that were
                previously reported on a November 30 year-end. This is being
                treated as a specified item as noted below.
 
      3)        2011 Taxes on earnings includes a favorable adjustment to tax
                expense of $580 million, or $0.37 per share, as a result of
                the resolution of various prior years' international and U.S.
                tax positions. This favorable item is classified as a
                specified item and excluded from ongoing results, as
                discussed below.
 
      4)        2011 Net Earnings Excluding Specified Items excludes
                after-tax charges of $1.454 billion, or $0.92 per share,
                related to litigation reserves, $673 million, or $0.43 per
                share, relating to acquired in-process research and
                development related to the Reata and Biotest collaborations,
                $341 million, or $0.22 per share, associated with the
                acquisition of Solvay Pharmaceuticals, $76 million, or $0.05
                per share, for the impairment of an R&D intangible asset,
                $137 million, or $0.09 per share, for the 2009 and 2010
                impact of the change to a calendar year end for international
                operations, $110 million, or $0.07 per share, for previously
                announced restructuring in the pharmaceutical business, $311
                million, or $0.19 per share, for cost reduction initiatives
                and other, and $80 million, or $0.05 per share, for other
                litigation reserves. These items were partially offset by a
                favorable adjustment from the resolution of prior years'
                international and U.S. tax positions for $580 million, or
                $0.37 per share.
 
                2010 Net Earnings Excluding Specified Items excludes
                after-tax charges of $1.035 billion, or $0.67 per share,
                associated primarily with the acquisitions of Solvay
                Pharmaceuticals and Piramal Healthcare Solutions, including
                announced restructuring plans, as well as other cost
                reduction initiatives, $313 million, or $0.20 per share,
                relating to acquired in-process research and development
                related to the Reata and the Neurocrine collaborations, $115
                million, or $0.07 per share, for the one-time impact of the
                devaluation of the Venezuelan bolivar on balance sheet
                translation, $106 million, or $0.07 per share, for a
                litigation reserve, $60 million, or $0.04 per share, for
                specific health care reform impact on deferred tax assets,
                $88 million, or $0.06 per share, for costs of a nutritional
                product recall and the withdrawal of sibutramine, and $158
                million, or $0.10 per share, for impairment of the intangible
                asset related to sibutramine.
 
    n/m = Percent change is not meaningful.
 

Questions & Answers

Q1) What drove sales growth in the quarter?

A1) Worldwide sales increased 4.1 percent to $10.4 billion in the quarter, including a favorable 0.2 percent effect of foreign exchange. With the significant movements in a number of exchange rates during the quarter, the favorable impact from exchange was almost 1 percent lower than our previous forecast.

Worldwide Nutritionals sales increased 8.6 percent in the quarter. International Nutritionals increased 10.8 percent, including 0.3 percent from favorable foreign exchange and driven by continued strong growth in emerging markets. U.S. Nutritionals increased 5.8 percent, with continued double-digit growth in PediaSure® and Ensure®. We also saw steady growth in International Vascular, Diabetes Care, Point of Care Diagnostics and Core Laboratory Diagnostics with continued ARCHITECT system placements. Molecular Diagnostics sales increased double-digits with the launch of new tests and uptake of the Ibis PLEX-ID platform.

Proprietary Pharmaceuticals sales increased 6.7 percent, including 0.4 percent from favorable foreign exchange, driven by strong growth across a number of key franchises in the United States and internationally including HUMIRA®, Androgel®, Creon®, Lupron® and Synthroid®.

Emerging markets sales were $2.5 billion, representing nearly 25 percent of total sales, with particularly strong growth in Nutritionals, Vascular and Diagnostics. In our Established Pharmaceuticals business, we had strong performance in Russia, India and China. In Nutritionals, we saw particularly strong growth in Asia and Latin America, where we are expanding our presence and gaining share with the introduction of new products. In our Vascular business, we had strong growth across many of our key emerging markets, driven by procedure volume and Abbott market share gains. And, in our Diagnostics business, we continue to perform well in Russia and China, where we are placing new ARCHITECT systems and continuing to penetrate the market.

Q2) What is the update on Abbott's planned separation into two leading health care companies?

A2) In October 2011, Abbott announced plans to separate into two publicly traded companies, one in diversified medical products and the other in research-based pharmaceuticals. The diversified medical products company will consist of Abbott's branded generic pharmaceutical, devices, diagnostic and nutritional businesses, and will retain the Abbott name. The research-based pharmaceutical company will include Abbott's current portfolio of proprietary pharmaceuticals and biologics and will be named later.

The transaction is intended to take the form of a tax-free distribution to Abbott shareholders of a new publicly traded stock for the new pharmaceutical company. The expected stock distribution ratio will be determined at a future date. It is expected that the two companies will each pay a dividend that, when combined, will equal the current Abbott dividend at the time of separation.

The separation process is being led by a dedicated team. We continue to expect the separation to be completed by the end of this year.

Q3) What was the gross margin ratio in the quarter?

A3) The gross margin ratio before and after specified items is shown below (dollars in millions):

 
                                             4Q11
                                                  
                                    Cost of              Gross      
                                    Products   Gross     Margin
                                      Sold     Margin      %
    As reported (GAAP)               $3,838    $6,539    63.0%
    Adjusted for specified items:
    Restructuring/integration/other   ($83)      $83      0.8%
    As adjusted                      $3,755    $6,622    63.8%

The adjusted gross margin ratio was 63.8 percent in the fourth quarter, an increase of 320 basis points over the fourth-quarter 2010. This was above our previous outlook for the quarter and driven by efficiency initiatives, favorable product mix, and the effect of foreign exchange.

Q4) What drove ongoing SG&A and R&D investment?

A4) Both ongoing SG&A and R&D investment reflect Abbott's continued investment in programs to drive future growth. Ongoing R&D expense as a percentage of sales was 10.2 percent, reflecting continued investment in Abbott's broad-based pipeline, including programs in vascular devices, diagnostics, nutritionals, immunology, neuroscience, oncology and HCV.

Q5) What was the tax rate?

A5) The ongoing tax rate this quarter was 14.6 percent, in line with expectations.

 
                                       4Q11
                              Pre-Tax  Taxes on   Tax
                              Income   Earnings   Rate
    As reported                $1,954     $335   17.1%
    Specified items              $732      $56    7.7%
    Excluding specified items  $2,686     $391   14.6%

Q6) How did specified items affect reported results?

A6) Specified items impacted fourth-quarter results as follows:

 
                                                                 4Q11
    (dollars in millions, except earnings-per-share)     Earnings
                                                       Pre-    After-
                                                       tax     tax     EPS
    As reported (GAAP)                                 $1,954  $1,619  $1.02
    Adjusted for specified items:
    Acquired in-process research and development         $400    $400  $0.25
    Restructuring/integration/other                      $332    $276  $0.18
    As adjusted                                        $2,686  $2,295  $1.45

Acquired in-process research and development is related to the agreement with Reata Pharmaceuticals to jointly develop and commercialize Reata's portfolio of second generation oral antioxidant inflammation modulators (AIMs).

Restructuring/integration/other is associated with restructuring and integration costs for the Solvay Pharmaceuticals acquisition. This item also includes previously announced cost reduction initiatives to improve efficiencies in the pharmaceutical, vascular, and core laboratory diagnostics businesses, along with certain new efficiency programs.

The impact of specified items by Consolidated Statement of Earnings line item is as follows (dollars in millions):

 
                                                       4Q11

                                    Cost of          Acquired           Other
                                    Products        in-process        (Income)/
                                     Sold     R&D       R&D     SG&A   Expense
    As reported (GAAP)               $3,838  $1,152    $400    $2,905    $28
    Adjusted for specified items:
    Acquired in-process research
    and development                    --      --     ($400)     --      --
    Restructuring/integration/other  ($83)   ($92)      --     ($120)   ($37)
    As adjusted                      $3,755  $1,060     --     $2,785   ($9)
 

Q7) What are the key areas of focus in Abbott's broad-based pipeline?

A7) We continue to advance our broad-based pipeline. In 2011, we launched several new products or indications, including XIENCE PRIME, XIENCE nano™, TREK® Coronary Balloon System, the RX Herculink Elite Renal Stent System, our ALK gene molecular diagnostics test, the FreeStyle® InsuLinx Blood Glucose Monitoring System, Glucerna Hunger Smart shakes and bars, Androgel 1.62%, Creon infant-specific dosage and three new variations of Lupron Depot. We also advanced elotuzumab and bardoxolone into Phase 3 development, and we now have more than 20 compounds or new indications in Phase 2 or Phase 3 development.

Following are highlights from breakthrough research across our pharmaceuticals, medical products and nutritionals pipelines:

  • Hepatitis C
    • Abbott's antiviral program is focused on developing treatments for hepatitis C (HCV), a disease that affects more than 180 million people worldwide, with approximately 3 to 4 million people newly infected each year. Abbott's broad-based HCV program includes three mechanisms of action in Phase 2b clinical trials, including protease, polymerase and NS5A inhibitors. Abbott is evaluating combinations of these compounds, both with and without the current standard of care, a strategy that has the potential to markedly transform current treatment practices by shortening therapy duration, improving tolerability and increasing cure rates. We expect additional data from our Phase 2b trials to be presented in 2012.
  • Chronic Kidney Disease
    • Bardoxolone, an investigational treatment for chronic kidney disease (CKD), is a first-in-class anti-inflammatory and anti-oxidant that activates Nrf2, a pathway involved in the progression of CKD. A global Phase 3 trial is currently underway. Abbott's agreement with Reata Pharmaceuticals includes international rights to bardoxolone, excluding certain Asian markets.
    • Also in development for the treatment of CKD is atrasentan, a compound discovered by Abbott scientists. A Phase 2b study in patients with diabetic kidney disease is ongoing with results expected in 2012.
  • Neuroscience / Pain
    • Abbott is conducting innovative research in neuroscience, where it has developed compounds that target receptors in the brain that help regulate mood, memory and other neurological functions. Abbott has 11 compounds in human studies for conditions such as schizophrenia, pain, Alzheimer's disease, Parkinson's disease and multiple sclerosis (MS).
    • Abbott's partnership with Biogen Idec includes development of a novel, next-generation antibody, daclizumab, which is currently in Phase 3 clinical trials for MS. Abbott is also continuing development of an intestinal gel for advanced Parkinson's disease and expects to submit a U.S. regulatory application in 2012.
  • Oncology
    • Abbott's oncology pipeline includes therapies that represent promising, unique scientific approaches to treating cancer. Abbott is focused on the development of targeted treatments that inhibit tumor growth and improve response to common cancer therapies.
    • Elotuzumab, an anti-CD37 antibody, is currently in Phase 3 development for multiple myeloma. Abbott is evaluating a number of promising mechanisms, including work on EGFR, Bcl2, PARP, aurora kinase and cMET, among others.
  • Immunology
    • Abbott's scientific experience with the anti-TNF biologic HUMIRA serves as a strong foundation for its continuing research in immunology. Abbott is developing a number of additional indications for HUMIRA and is working to advance its early discovery programs, including oral DMARD therapies, and other potential biologic targets.
    • We recently announced plans to jointly develop and commercialize Reata's portfolio of second-generation oral antioxidant inflammation modulators. The global agreement includes a large number of molecules in a broad range of therapeutic areas, including pulmonary, central nervous system disorders and immunology.
    • Additionally, Abbott's proprietary DVD-Ig technology represents an innovative approach that can target multiple disease-causing antigens with a single biologic agent. This technology could lead to combination biologics for complex conditions such as cancer or rheumatoid arthritis, where multiple pathways are involved in the disease. We recently advanced two DVD-Ig molecules into Phase 1 clinical trials.
  • Women's Health
    • Elagolix, a novel, first-in-class oral gonadotropin-releasing hormone (GnRH) is in development for the treatment of endometriosis-related pain and fibroids. Abbott is working in partnership with Neurocrine to finalize the Phase 3 study design in endometriosis and a Phase 2 study in uterine fibroids was recently initiated.
  • Vascular Devices
    • Abbott has one of the industry's most robust vascular pipelines and is working on well-staged incremental advances, and truly game-changing technologies that have the ability to restate the market.
    • Bioresorbable Vascular Scaffold (BVS) - Abbott has the most advanced BVS clinical program in the industry. Absorb, the world's first drug-eluting BVS for the treatment of coronary artery disease, restores blood flow to the heart by opening a clogged vessel and providing support to the vessel until the device dissolves, leaving patients with a treated vessel free of a permanent metallic implant. Absorb received CE Mark and is authorized for sale in Europe. In 2011, Abbott initiated several clinical trials, evaluating its BVS for the treatment of coronary and peripheral artery disease.
    • MitraClip - MitraClip® is a minimally invasive device for the treatment of select patients with mitral regurgitation (MR), the most common valve disease in the world. Significant MR affects more than 8 million people in the United States and Europe, and is four times more prevalent than aortic stenosis. Abbott's MitraClip system is on the market in Europe and a number of other countries and is currently under U.S. FDA review.
    • Drug Eluting Stents (DES) - Abbott has several next-generation DES platforms on the market and in development. With U.S. FDA approvals in 2011, XIENCE PRIME and XIENCE nano for small vessels are now available in Europe and in the United States. Also in development is XIENCE Xpedition, our next-generation DES that offers a new catheter for enhanced deliverability, as well as a broader size matrix. We expect Xpedition to launch in Europe this year and in the U.S. in 2013.
    • Core Coronary products - Abbott is continuing to expand its position in the more-than-$2 billion core coronary market. Abbott's next-generation balloon dilatation catheter, TREK®, is available in the United States, Europe and Japan, and Abbott plans to introduce additional balloon catheter products and next-generation guide wires within the next few years.
    • Endovascular products - Abbott's endovascular business continues to grow, led by recent launches of key products, including the Armada peripheral balloon line, the expanded indication for the RX ACCULINK® Carotid Stent System, and R&D investments in peripheral artery disease and vessel closure. In 2011, we launched the RX Herculink Elite Renal Stent System in the U.S. for the treatment of renal artery stenosis in patients with uncontrolled hypertension. In 2012, we expect to launch the Absolute Pro and Omnilink Elite stents for iliac indications in the United States.
  • Molecular Diagnostics
    • In 2011, Abbott received U.S. FDA approval and CE Mark for an ALK gene rearrangement test for non-small-cell lung cancer to be used in combination with Pfizer's XALKORI (crizotinib), an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor. Abbott also recently received FDA clearance for the Vysis EGR1 FISH Probe Kit to aid in determining the prognosis of patients with acute myeloid leukemia. Additionally, Abbott received FDA approval for the Abbott RealTimePCR HCV assay for measuring viral load, or the amount of hepatitis C virus in a patient's blood, as well as CE Mark for a new test to detect cytomegalovirus (CMV), a virus that can lead to complications in transplant patients and people who are immunocompromised.
    • Abbott expects to launch more than 15 new molecular diagnostic products over the next few years, including several novel oncology and infectious disease assays.
  • Core Laboratory Diagnostics
    • Abbott has launched a number of key assays on its ARCHITECT immunochemistry platform, which will significantly broaden its industry-leading menu. These tests include assays to assess ovarian cancer, vitamin deficiencies, and the first HIV combination assay approved for use in the United States. Future growth for the Core Laboratory Diagnostics business will be driven by differentiated analyzers and comprehensive automation and informatics solutions to provide high-quality results and information while enhancing laboratory productivity and reducing costs.
  • Vision Care
    • Abbott expects numerous new products and technology advancements over the next five years. In its market-leading LASIK business, Abbott is expanding its proprietary laser platform into new vision correction applications, including cataract surgery. Abbott also continues to expand its portfolio of premium and standard intraocular lenses (IOL).
  • Nutrition
    • Abbott is focused on improving six areas through nutrition: immunity, cognition, lean body mass, inflammation, metabolism and tolerance. In 2011, Abbott introduced several new products, including Ensure with Revigor™, PediaSure SideKicks™, ZonePerfect® Sweet & Salty nutrition bars, Glucerna Hunger Smart shakes and bars, and Similac Mom, a nutritional supplement for pregnant and lactating women. We expect to launch a number of new products and formulations to consumers in 2012 and are currently conducting 30 well-controlled clinical trials to demonstrate proven clinical outcomes with our nutrition innovation.

Modal title

Also from this source

New Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott's Volt™ PFA System for Patients with AFib

New Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott's Volt™ PFA System for Patients with AFib

Abbott (NYSE: ABT) has announced new data from its Volt CE Mark Study that show strong safety and efficacy out to 12 months for patients receiving...

Abbott Receives CE Mark for its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms

Abbott Receives CE Mark for its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms

Abbott (NYSE: ABT) today announced it has received CE Mark in Europe for the Volt™ PFA System to treat patients battling atrial fibrillation (AFib)....

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

Dividends

Dividends

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.